We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-7.9%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
-$202M
Cap. Flow
+$27.4M
Cap. Flow %
1.97%
Top 10 Hldgs %
51.89%
Holding
98
New
17
Increased
22
Reduced
21
Closed
23

Top Buys

Rank Stock Value
1
BBNX
Beta Bionics
BBNX
+$63.3M
2
NVCR icon
NovoCure
NVCR
+$63.2M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$56M
4
STAA icon
STAAR Surgical
STAA
+$51.4M
5
HOLX
Hologic
HOLX
+$20M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$29.3M
2
AXGN icon
Axogen
AXGN
+$27.2M
3
AZN icon
AstraZeneca
AZN
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$24.4M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LIVN icon
51
LivaNova
LIVN
$4.13B
$4.6M 0.33%
+117,040
New +$5.25M
SEPN
52
Septerna Inc
SEPN
$1.74B
$4.35M 0.31%
751,353
+75,944
+11% +$867K
GERN icon
53
Geron
GERN
$975M
$3.82M 0.27%
+2,400,000
New +$5.84M
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.76B
$3.7M 0.27%
+58,000
New +$6.11M
EPIX
55
DELISTED
ESSA Pharma
EPIX
$3.57M 0.26%
2,262,026
– –
MYO icon
56
Myomo
MYO
$51.5M
$3.39M 0.24%
704,275
-195,725
-22% -$1.12M
RVMD icon
57
Revolution Medicines
RVMD
$42.2B
$3M 0.22%
84,784
-116,300
-58% -$4.72M
DCTH icon
58
Delcath Systems
DCTH
$535M
$2.96M 0.21%
232,722
-568,278
-71% -$8.07M
ERAS icon
59
Erasca
ERAS
$6.21B
$2.96M 0.21%
2,162,162
– –
NSPR icon
60
InspireMD
NSPR
$34.2M
$2.54M 0.18%
945,376
-432,752
-31% -$1.22M
SION
61
Sionna Therapeutics
SION
$2.28B
$2.51M 0.18%
+240,000
New +$3.92M
AXSM icon
62
Axsome Therapeutics
AXSM
$10.8B
$1.98M 0.14%
+17,000
New +$1.94M
ANAB icon
63
AnaptysBio
ANAB
$1.68B
$1.9M 0.14%
102,052
-311,948
-75% -$5.2M
DNLI icon
64
Denali Therapeutics
DNLI
$3.86B
$1.84M 0.13%
+135,000
New +$2.59M
EWTX icon
65
Edgewise Therapeutics
EWTX
$4.6B
$1.59M 0.11%
72,300
-111,000
-61% -$2.91M
YMAB
66
DELISTED
Y-mAbs Therapeutics
YMAB
$1.55M 0.11%
349,982
– –
MREO
67
Mereo BioPharma
MREO
$47.8M
$1.55M 0.11%
686,953
-100,000
-13% -$283K
CALC icon
68
CalciMedica
CALC
$10.9M
$1.5M 0.11%
783,904
– –
TECX
69
Tectonic Therapeutic
TECX
$584M
$1.36M 0.1%
76,841
+45,000
+141% +$1.47M
ADVM
70
DELISTED
Adverum Biotechnologies
ADVM
$1.26M 0.09%
287,246
– –
KIDS icon
71
OrthoPediatrics
KIDS
$596M
$1.11M 0.08%
+45,000
New +$1.11M
ABVX
72
Abivax
ABVX
$11.4B
$781K 0.06%
125,000
– –
APGE icon
73
Apogee Therapeutics
APGE
$10.2B
$598K 0.04%
16,000
-54,000
-77% -$2.09M
IOBT
74
DELISTED
IO Biotech
IOBT
$210K 0.02%
192,670
– –
ADPT icon
75
Adaptive Biotechnologies
ADPT
$3.9B
$74.3K 0.01%
10,000
-2,973,142
-100% -$22.9M
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Soleus Capital Management held 98 positions worth $1.39B, down 13% from $1.59B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Soleus Capital Management's Q1 2025 filing shows 17 new, 22 increased, 21 reduced and 23 closed positions. Its largest new stake was Beta Bionics: 3,395,341 shares worth $41.6M. The largest sale was Teva Pharmaceuticals, an estimated $29.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier.

  • Soleus Capital Management's largest Q1 2025 buy was Beta Bionics: 3,395,341 shares worth $41.6M.
  • Soleus Capital Management added most to NovoCure in Q1 2025, an estimated $63.2M increase.
  • Soleus Capital Management's biggest Q1 2025 reduction was Teva Pharmaceuticals, cutting an estimated $29.3M.
  • Soleus Capital Management fully exited AstraZeneca in Q1 2025, selling an estimated $26.8M.
  • Soleus Capital Management's ten largest holdings make up 52% of its $1.39B portfolio in Q1 2025.
  • Soleus Capital Management opened 17 new positions and closed 23 in Q1 2025.
  • Soleus Capital Management's portfolio value fell 13% quarter-over-quarter to $1.39B.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.